IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome

Leukemia

Volumn 30, Issue 1, 2016, Pages 253-257

  Landberg, N ^a   Hansen, N ^a   Askmyr, M ^a   Agerstam H ^a   Lassen, C ^a   Rissler, M ^a   Hjorth Hansen, H ^b,c   Mustjoki, S ^d   Jaras M ^a   Richter, J ^e   Fioretos, T ^a  

^a LUND UNIVERSITY   (Sweden)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d UNIVERSITY OF HELSINKI   (Finland)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD123 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; DASATINIB; IMATINIB; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; BCR-ABL1 FUSION PROTEIN, HUMAN; IL1RAP PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; CLINICAL PROTOCOL; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC STEM CELL; HUMAN; LETTER; LEUKEMIC STEM CELL; LEUKOCYTE COUNT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; TREATMENT RESPONSE; UPREGULATION; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CHEMISTRY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATHOLOGY; TREATMENT OUTCOME;

ANTIGENS, CD34; ANTIGENS, CD38; FUSION PROTEINS, BCR-ABL; HUMANS; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84953352071     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.135     Document Type: Letter

References (15)

1. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-183.
2. Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010; 24: 1823-1833.
3. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653.
4. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. 2013Blood 2013; 122: 872-884.
5. Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy Clin Cancer Res 2014; 20: 310-322.
6. Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia 2013; 27: 1520-1526.
7. Jaras M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA 2010; 107: 16280-16285.
8. Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzl G, Willmann M et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood 2014; 123: 3951-3962.
9. Nievergall E, Ramshaw HS, Yong ASM, Biondo M, Busfield SJ, Vairo G et al. Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes CML progenitor and stem cells. Blood 2014; 123: 1218-1228.
10. Florian S, Sonneck K, Hauswirth AW, Krauth M-T, Schernthaner G-H, Sperr WR et al. Detection of molecular targets on the surface of CD34+/CD38-stem cells in various myeloid malignancies. Leuk Lymphoma 2006; 47: 207-222.
11. Levescot A, Flamant S, Basbous S, Jacomet F, Feraud O, Anne Bourgeois E et al. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34(+) progenitors from chronic myeloid leukemia patients. Cancer Res 2014; 74: 2669-2676.
12. Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol 2014; 94: 243-250.
13. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232-238.
14. Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096-2102.
15. Janssen JJ, Deenik W, Smolders KG, van Kuijk BJ, Pouwels W, Kelder A et al. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Leukemia 2011; 26: 977-984.